Loading…

Wuxi Apptec2359.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Pharmaceuticals: Major

Chinese contract research and manufacturing organization helping global drugmakers discover, test and produce medicines.

≈ China's Lonza/Catalent, with a large CRO arm tooMomentum leader 92
Mkt cap
$64.1B
US dollars, full cap
Free float
95%
of shares outstanding
$/day
$194M
20-day average traded
Fwd P/E
19.5×
forward earnings
ROIC−WACC
+29.1 pp
WACC 10.0%
Hurdle
-12 pp
Req g minus delivered
Next earnings
124 days
22 Mar 2027
Close · HKDHK$189.90
1D-1.5%
1W-3.4%
1M-3.4%
3M-6.0%
6M+50.6%
YTD+94.3%
1Y+86.8%
ATR %5.6%
52w lowhigh13.4% off high

What Wuxi Apptec does

Chinese contract research and manufacturing organization helping global drugmakers discover, test and produce medicines.

Is paid by drugmakers for work on their projects, starting with discovery chemistry and testing and moving into process development and manufacturing as a drug advances. Most customers are outside China, mainly in the US. It sold its US and UK cell and gene therapy units in 2025. These Hong Kong shares and the Shanghai ones are the same company.

In one line: China's Lonza/Catalent, with a large CRO arm too.

Products and services

  • Small-molecule CRO (discovery/testing)
  • CDMO manufacturing
  • Clinical trial services
  • Cell and gene therapy services

Customers

  • Global pharma and biotech companies

Where it sits in the supply chain

  • Healthcare services
  • Contract research and manufacturing…
  • Drug discovery, testing, process…

What could go right

  • Global biotech outsourcing demand
  • New-modality (ADC, peptide) manufacturing

What could go wrong

  • US biosecurity/BIOSECURE Act restrictions
  • US-China biotech tension

Moat: narrow (scale, switching costs, process know-how). Deep integrated discovery-to-manufacturing platform makes switching costly once a drug program is embedded.

Headquarters: Shanghai, China · Founded: 2000 · Employees: 33,834

Named competitors

Wuxi Apptec at a glance

Size Wuxi Apptec (2359.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $64.1B, the 30th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$189.90 on 18 Nov 2026.

Performance Over six months the shares gained 50.6%, against +11.2% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — highest of 21 in its peer set.

Growth Revenue grew 38.3% over the last twelve months (peer median +8.8%); the operating margin is 43.5% (peer median 23.2%).

Valuation It trades at 19.5× forward earnings against a peer median of 17.0× (8th most expensive of 21).

Price implies For today's price to make sense, revenue must grow about 8% a year for seven years (Req g). Recent delivered growth is +20%, so the hurdle is -12 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 29.1 points above its cost of capital (10.0% WACC).

Next results Next results expected around 22 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012515017521 May 202621 Aug 202618 Nov 20262359.HK 147Peer median 113
Six months, rebased to 100: Wuxi Apptec against the median of its 20 peers (local-currency closes).

Wuxi Apptec financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$64.4BHK$47.1BHK$38.8BHK$42.7BHK$45.8B
Revenue growth—+21%-9%-7%—
Gross profitHK$35.6BHK$22.7BHK$17.1BHK$18.0BHK$16.9B
EBITDAn/aHK$20.9BHK$15.2BHK$15.1BHK$12.8B
Net incomeHK$30.1BHK$20.8BHK$10.1BHK$11.8BHK$10.2B
Free cash flown/aHK$13.1BHK$8.96BHK$7.69BHK$429M
Capital expendituren/aHK$6.01BHK$4.34BHK$6.10BHK$11.6B
Total debtHK$9.98BHK$9.38BHK$9.06BHK$6.34BHK$6.73B

Quarterly statements and history in the cockpit →

Wuxi Apptec competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%0%+10%BAYN4502MRK4519GALDSUNPHARMA600276688235REGNGSKSDZ4578HLNRPRXBIIBSANZTSBMY450345682359.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Wuxi Apptec is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%+30%20×40×BAYN4502MRK4519GALDSUNPHARMA600276688235REGNGSKSDZ4578RPRXSANBMY45682359.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Wuxi Apptec is the large dot.

Capital: growth delivered against growth the price implies

0%+25%+50%+75%0%50%4502MRK4519GALDSUNPHARMA600276688235REGNGSKSANBMY450345682359.HKGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Wuxi Apptec is the large dot.

Wuxi Apptec competitors and peer comparison

Head to head with its named competitors (2359.HK vs 2269.HK vs LONN.SW vs 207940.KS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Wuxi Apptec 2359.HK$64.1B+51%+38%44%19.5×8.4%
Wuxi Bio 2269.HK$23.1B+35%+22%32%26.5×20.8%
Lonza LONN.SW$53.9B+36%-11%25%36.1×15.6%
Samsung Biologics 207940.KS$48.7B-6%-20%43%34.4×7.0%
Charles River Laboratories CRL$16.0B+114%-1%15%26.2×25.6%

How Wuxi Apptec compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Wuxi Apptec against its 20 peers (data as of 18 Nov 2026)
Measure2359.HKPeer medianRank in peer set
1-month return-3.4%+6.3%3rd lowest of 21
6-month return+50.6%+11.2%highest of 21
Distance from 52-week high-13.4%-5.5%8th lowest of 21
Revenue growth (TTM)+38.3%+8.8%highest of 21
Operating margin43.5%23.2%3rd highest of 21
Forward P/E19.5×17.0×8th most expensive of 21
Growth the price implies (Req g, 7 yrs)8.4%5.2%7th most demanding of 20
Growth delivered (Del g)+20.4%+6.4%2nd highest of 20
Hurdle (Req g minus delivered)-12.1 pp-3.4 pp5th least demanding of 20
ROIC minus cost of capital+29.1 pp+4.8 pp3rd highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Wuxi Apptec 2359.HKHong Kong$64.1B+51%+38%44%19.5×8.4%+20.4%
Bayer BAYN.DEGermany$60.3B+48%0%13%12.3×n/an/a
Takeda Pharmaceutical 4502.TJapan$69.8B+30%+6%18%51.0×3.7%+7.1%
Merck KGaA MRK.DEGermany$71.3B+16%+1%19%17.4×7.4%+3.8%
Chugai Pharmaceutical 4519.TJapan$75.2B-8%+17%50%23.7×5.0%+9.8%
Galderma GALD.SWSwitzerland$51.9B+18%+16%19%45.7×18.0%+6.4%
Sun Pharmaceutical Industries SUNPHARMA.NSIndia$48.0B-1%+12%23%36.0×28.7%+11.7%
Jiangsu Hengrui Pharmaceuticals 600276.SSChina$45.7B-13%+6%27%33.4×13.4%+2.7%
BeOne Medicines 688235.SSChina$45.5B+9%+25%18%59.7×19.1%+79.3%
Regeneron Pharmaceuticals REGNUnited States$97.8B+46%+19%30%11.8×-1.1%+11.0%
GSK GSK.LUnited Kingdom$97.9B-3%+4%25%10.4×-0.1%-0.9%
Sandoz SDZ.SWSwitzerland$41.7B+26%+1%15%24.5×7.5%+0.4%
Otsuka Hldgs 4578.TJapan$39.9B+9%+11%18%16.8×1.6%+11.7%
Haleon HLN.LUnited Kingdom$39.6B0%+1%23%16.4×5.2%+2.2%
Royalty Pharma RPRXUnited States$39.4B+29%+11%66%11.5×10.8%+2.3%
Biogen BIIBUnited States$37.2B+34%+2%17%17.1×10.1%-5.1%
Sanofi SAN.PAFrance$114B+13%+15%27%9.7×-4.8%+3.9%
Zoetis ZTSUnited States$34.8B+7%+1%37%13.8×-2.9%+7.2%
Bristol Myers Squibb BMYUnited States$122B+3%+4%33%9.2×-13.1%+2.5%
Astellas Pharma 4503.TJapan$31.4B+17%+19%23%12.9×-9.0%+11.4%
Daiichi Sankyo 4568.TJapan$31.4B+8%+17%13%18.4×7.6%+17.1%

Questions

Who are Wuxi Apptec's main competitors?
Named competitors: WuXi Biologics (2269.HK), Lonza (LONN.SW), Samsung Biologics (207940.KS), Charles River Laboratories (CRL). The cockpit's measured peer set (industry) also includes Bayer (BAYN.DE), Takeda Pharmaceutical (4502.T), Merck KGaA (MRK.DE), Chugai Pharmaceutical (4519.T), Galderma (GALD.SW), Sun Pharmaceutical Industries (SUNPHARMA.NS).
Is Wuxi Apptec expensive compared with its peers?
On forward p/e it trades at 19.5× against a peer median of 17.0×, 8th most expensive of 21 in its peer set. For today's price to make sense, revenue must grow about 8% a year for seven years (Req g). Recent delivered growth is +20%, so the hurdle is -12 pp: the price already allows for a slowdown.
How has Wuxi Apptec stock performed?
Over six months to 18 Nov 2026 the shares returned +50.6% against +11.2% for the median peer; over one year +86.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.